Clinical Trial Protocol
Iranian Registry of Clinical Trials

25 Jun 2026

Comparative Bioequivalence Study of the Ursodeoxycholic acid 300-mg Capsule Produced by Modava Pharmaceutical Co. versus Ursobil® (Bionika Company).

Protocol summary

Study aim

Demonstration of bioequivalence of Ursodeoxycholic acid 300 mg Capsule of Modava Pharmaceutical Company with Ursobil® Capsule manufactured by Bionika company after single dose administration.

Design

Single dose, randomized and crossover bioequivalence study of Ursodeoxycholic acid 300-mg Capsule by Modava Co. with Ursobil® (Bionika Co.) in 24 healthy male volunteers in two groups under fasting condition.

Settings and conduct

Study place and the place for Blood sample analysis are the Drug Applied Research Center affiliated to Tabriz University of Medical Science, respectively. 24 healthy male volunteers will receive each of test or reference Ursodeoxycholic acid 300-mg Capsule in random sequence according to the randomization schedule. The interval between receiving the medicine (washout period) is 14 days, If the first sequence receives domestic medicine, they will receive brand medicine. Blood samples will be taken from all participants before and after receiving the drug at 1 and 2 hours before dosing, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 24, 48 and 72 hours after dosing.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Healthy male subjects in the age range of 18-60 years and BMI (Body Mass Index) of 18-30. Exclusion criteria: Subjects with Blood Pressure ≤ 90/60 mm/Hg or BP ≥ 140/90 mm/Hg. Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function or a history of tuberculosis, epilepsy, asthma, diabetes, psychosis or glaucoma and regular smoker.

Intervention groups

Intervention group 1: Ursodeoxycholic acid 300-mg Capsule by Modava Co. is the test product. Intervention group 2: Ursobil® (Bionika Co.) is the reference product. In each period, 12 of 24 subjects will be given single dose of this product.

Main outcome variables

Peak Plasma Concentration (Cmax); Area under the concentration-time curve (AUC).

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200407046981N41**
Registration date: **2022-10-08, 1401/07/16**
Registration timing: **prospective**

Last update: **2022-10-08, 1401/07/16**
Update count: **0**

Registration date

2022-10-08, 1401/07/16

Registrant information

Name
Fatima Molavi
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 41 3336 2700
Email address
molavif@tbzmed.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-02-20, 1401/12/01

Expected recruitment end date

2023-05-22, 1402/03/01

Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty

Scientific title
Comparative Bioequivalence Study of the Ursodeoxycholic acid 300-mg Capsule Produced by Modava Pharmaceutical Co. versus Ursobil® (Bionika Company).

Public title
Study of absorption and elimination rate of Ursodeoxycholic acid 300-mg Capsule in comparison with Ursodeoxycholic acid brand Capsule (Ursobil®).
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
The weight limit of each volunteer should be between 60 and 100 kg. All volunteers must be non-smokers. They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed. Candidates who have consented to the consent form.
Exclusion criteria:
Known hypersensitivity or idiosyncratic reaction to Ursodeoxycholic acid or any ingredients. Subjects with BP ≤ 90/60 mm/Hg or BP ≥ 140/90 mm/Hg. Taking any medicine during two weeks before dosing.
Age
From **18 years** old to **60 years** old
Gender
Male

Phase
Bioequivalence
Groups that have been masked
No information
Sample size
Target sample size: **24**
Randomization (investigator's opinion)
Randomized
Randomization description
To randomly assign people in two groups, 24 cards with numbers 1 to 24 will be used in closed envelopes that are arranged irregularly. Each candidate will pick up an envelope after entering the study, and numbers 1-12 will be in group A and numbers 13-24 will be in group B. Group A will receive intervention 1 and group B will receive intervention 2, and after the first period, the interventions of the both groups will change for the second period.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Crossover
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Tabriz University of Medical Science
Street address
Third floor, central building No. 2, Golgasht street, Tabriz University of Medical Science, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5166614766
Approval date
2022-04-17, 1401/01/28
Ethics committee reference number
IR.TBZMED.REC.1401.567

Health conditions studied

1

Description of health condition studied
Bioequivalence study
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
Peak Plasma Concentration (Cmax)
Timepoint
At 1 and 2 hours before dosing, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 24, 48 and 72 hours after dosing
Method of measurement
High-performance liquid chromatography—mass spectrometry (HPLC-MS)

Secondary outcomes

1

Description
AUC (Area Under the Concentration-Time Curve)
Timepoint
At 1 and 2 hours before dosing, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 24, 48 and 72 hours after dosing
Method of measurement
Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA) or SPSS

Intervention groups

1

Description
Intervention group 1: In this group, volunteers are given a single oral dose of Ursodeoxycholic acid 300-mg Capsule produced by Modava Co. (Domestic). In each period, 12 of 24 subjects will be given single oral dose of this product.
Category
Treatment - Drugs

2

Description
Intervention group 2: In this group, volunteers are given a single oral dose of Ursodeoxycholic acid 300-mg Capsule (Ursobil), produced by Bionika Company (Brand). In each period, 12 of 24 subjects will be given single oral dose of this product.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Drug Applied Research Center
Full name of responsible person
Hamed Hamishehkar
Street address
Drug Applied Research Center, In front of Shahid Madani Hospital, Daneshghah Blvd, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5165665811
Phone
+98 41 3336 7914
Fax
+98 41 3336 7914
Email
Hamishehkar.hamed@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Modava pharmaceutical company
Full name of responsible person
Farrokh Rahimzadeh
Street address
Unit.5, No. 275, Shahid Beheshti St., Modava Pharmacy
City
Tehran
Province
Tehran
Postal code
1514617714
Phone
+98 21 8817 4996
Email
r.otadi@modavaco.com
Web page address
http://www.modavapharma.com/
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Modava pharmaceutical company
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Industry

Person responsible for general inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Fatima Molavi
Position
Non-Faculty Academic Position
Latest degree
Ph.D.
Other areas of specialty/work
Pharmaceutics
Street address
ایران، تبریز، خیابان دانشگاه، روبروی بیمارستان شهید مدنی، مجتمع تحقیق و توسعه دانشگاه علوم پزشکی تبریز، مرکز تحقیقات کاربردی دارویی
City
Tabriz
Province
East Azarbaijan
Postal code
5165665811
Phone
+98 41 3336 7914
Email
F.molavi85@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Hamed Hamishehkar
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Pharmaceutics
Street address
Drug Applied Research Center, In front of Shahid Madani Hospital, Daneshghah Blvd, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5165665811
Phone
+98 41 3336 7914
Email
Hamishehkar.hamed@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Fatima Molavi
Position
Non-Faculty Academic Position
Latest degree
Ph.D.
Other areas of specialty/work
Pharmaceutics
Street address
ایران، تبریز، خیابان دانشگاه، روبروی بیمارستان شهید مدنی، مجتمع تحقیق و توسعه دانشگاه علوم پزشکی تبریز، مرکز تحقیقات کاربردی دارویی
City
Tabriz
Province
East Azarbaijan
Postal code
5165665811
Phone
+98 41 3336 7914
Email
F.molavi85@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
No - There is not a plan to make this available
Justification/reason for indecision/not sharing IPD
There is no further information
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Not applicable
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available